Immunologically, inhibition of MEK signaling reduces the proliferation of T cells in vitro and prolonged blockade of T cell receptor signaling by MEK inhibitors interferes with effector function and proliferation at the tumor site (13–15). Here, MAP2K7 is linked to neoplasm.